Delta sleep-inducing peptide (DSIP) is a nine-residue peptide that a Swiss research group isolated in the 1970s and named after changes in slow-wave, or delta, EEG activity in rabbits. Half a century later it remains one of the odder molecules in neuropeptide research: it has been reported to act in many systems, yet no gene, precursor protein or dedicated receptor for it has ever been found.
That gap is the main reason DSIP still draws attention. This article goes through its discovery, the structural and stability work, the neuroendocrine, mitochondrial and EEG studies that make up most of the literature, and the reasons reviewers describe the field as unresolved.
At a glance
- Class: Linear nonapeptide; endogenous gene and receptor unidentified
- Origin: Isolated from rabbit cerebral venous blood by Monnier, Schoenenberger and colleagues in Switzerland in the 1970s
- Structure: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu; C35H48N10O15; MW 848.8 g/mol; CAS 62568-57-4
- Main research areas: EEG and sleep architecture in animals, pituitary and pineal regulation, mitochondrial respiration under hypoxia, glutamate receptor interactions, peptide stability
- Regulatory status: Not approved by the FDA for any use; research reagent only
Structure and origin
The discovery came from a classic transfer experiment. Researchers in Basel electrically stimulated the thalamus of rabbits at low frequency to produce sleep-like EEG patterns, collected cerebral venous blood, and looked for a factor that could transfer those patterns to recipient animals. The active material was purified, sequenced as a nonapeptide, and then synthesized. Monnier and colleagues compared the original isolate with the synthetic peptide and reported similar properties in their rabbit preparations (Monnier et al., 1977).
The sequence is short, linear and rich in small residues: five of its nine amino acids are glycine or alanine, with an N-terminal tryptophan and acidic residues at positions 5 and 9. It carries no disulfide bond and no C-terminal amide. DSIP-like immunoreactivity was later reported in the brain, pituitary and several peripheral tissues, and in plasma. Yet searches of the genome have not found a gene encoding the peptide, and no specific high-affinity receptor has been cloned. Reviewers have proposed that DSIP may be a fragment of a larger, still unknown protein, or that the immunoreactive material differs from the synthetic sequence (Kovalzon & Strekalova, 2006).
Mechanism: what the research shows
Without a receptor, mechanism studies have relied on pharmacological interactions in tissue preparations. In rat pineal glands, Graf and Schoenenberger found that DSIP modulated the stimulation of N-acetyltransferase, the enzyme that controls melatonin synthesis, and that this effect involved the α1-adrenergic receptor (Graf & Schoenenberger, 1987). Other groups reported DSIP effects on release of luteinizing hormone, corticotropin and growth hormone in rats, and electrophysiology work suggested that some neuronal responses depended on NMDA-type glutamate receptors.
A separate line of work looked at energy metabolism. Using isolated rat brain mitochondria, Khvatova and colleagues measured respiration and oxidative phosphorylation in the presence of DSIP and examined its effect in an experimental hypoxia model (Khvatova et al., 2003). These studies suggest the peptide may act at several points, but they do not identify a primary target.
Key areas of study
EEG and sleep architecture in animals
The original studies measured EEG in rabbits, and later work extended this to rats and cats. Results varied: some laboratories reported increases in slow-wave or paradoxical sleep, others found little or no effect, and timing, route and species all seemed to matter. A 1988 review framed DSIP as a tool for investigating mechanisms of sleep onset rather than as an established sleep factor (Yehuda & Carasso, 1988).
Neuroendocrine regulation
The pineal N-acetyltransferase study is one of the more mechanistically specific DSIP papers, linking the peptide to adrenergic control of melatonin synthesis in rat tissue (Graf & Schoenenberger, 1987). Pituitary hormone studies in rats add to this picture, though their findings were not consistent across laboratories (Kovalzon & Strekalova, 2006).
Mitochondria and hypoxia
Mitochondrial respiration assays and hypoxia models provide a biochemical angle on DSIP that does not depend on EEG recordings (Khvatova et al., 2003). This work is often cited in discussions of the peptide as a stress-protective agent in animal models, a label that remains descriptive rather than mechanistic.
Stability and analog design
DSIP is cleaved rapidly in vitro by aminopeptidase-like enzymes that remove the N-terminal tryptophan. That instability led to modified analogs used to probe structure-activity relationships, and it complicates interpretation of in vivo work, because the intact peptide may persist only briefly (Kovalzon & Strekalova, 2006).
What the evidence does not show
The most important gap is basic: there is no known gene, precursor or receptor, so DSIP cannot yet be placed in a defined signaling system. Much of the literature dates from the 1970s to the 1990s, uses small groups of animals and older methods, and reports findings that other laboratories could not always reproduce. Effects on EEG differ between species and protocols. The rapid breakdown of the peptide raises questions about what reaches target tissue in any in vivo experiment. Reviewers have called DSIP “a still unresolved riddle” for these reasons (Kovalzon & Strekalova, 2006). None of these animal or tissue studies establishes an effect in people, and none describes the material sold here.
Regulatory status
DSIP is not approved by the FDA for any use. Rogue Compounds sells it as a research reagent only.
Handling and storage in the lab
Lyophilized DSIP should be kept sealed and refrigerated at 2–8°C (36–46°F), protected from light. The N-terminal tryptophan is light- and oxidation-sensitive, which is one more reason to keep the vial closed and shielded until use.
Sourcing and documentation
Rogue Compounds has DSIP made in small batches. Every vial carries a batch number and a QR code that opens the independent U.S. testing lab’s own report for that batch. The same batch COA is posted on the product page and in the COA Library.
References
- Monnier M, et al. The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide. Experientia. 1977;33(4):548-552. PMID 862769
- Graf MV, Schoenenberger GA. Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the α1-adrenergic receptor. J Neurochem. 1987;48(4):1252-1257. PMID 3029331
- Yehuda S, Carasso RL. DSIP—a tool for investigating the sleep onset mechanism: a review. Int J Neurosci. 1988;38(3-4):345-353. PMID 3286557
- Khvatova EM, et al. Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia. Peptides. 2003;24(2):307-311. PMID 12668217
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309. PMID 16539679
Research use only. Rogue Compounds products are sold strictly for laboratory research. They are not for human or veterinary use, and nothing in this article is medical advice. The studies cited here describe published research, not this product or any use of it.